Celgene reports 'durable' responses to multiple myeloma CAR-T in early trial despite relapses

Celgene and its development partner, Bluebird Bio, released interim data from a phase 1 study of bb2121 Thursday, with the study’s senior author declaring “deep and durable responses” to the engineered cell therapy. Of the first 33 patients who were treated in the trial, 15 experienced full responses and nine had partial responses, the companies said. The study was published in The New England Journal of Medicine.